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Progress in understanding tumor-specific immune responses, genetic engineering and ex 
vivo manufacturing, have led to improvements in the safety and feasibility of adoptive 
transfer of genetically modified T cells. However, rational design, application and evaluation 
of T-cell therapy requires monitoring methods that can detect, locate and serially quantify 
these cell-mediated immune responses. Currently, such monitoring methods are chiefly 
limited to invasive techniques to investigate recovered cell populations for in vitro 
measurements including histology, flow cytometry, Q-PCR or the detection of cytokines. 
These assays provide episodic glimpses of the bio distribution of T cells and are limited by 
the number and sites of sampling. In contrast, imaging provides a methodology for 
quantitative, non-invasive, longitudinal and spatial in vivo information about the dynamic 
processes of infused T cells.
In earlier studies, in vivo imaging of lymphocyte migration used cells passively labeled with 
radiotracers ex vivo. An alternative imaging approach involves stable transduction/
transfection of cells with a reporter gene (such as herpes simplex virus-1 thymidine kinase; 
HSV-TK) that can be visualized by active accumulation of a radiolabeled reporter probe. It 
has been demonstrated that cells genetically modified to express HSV-TK could be imaged 
by scintigraphy or positron emission tomography (PET) in rodents after infusions of I-
labeled 2′-fluoro-2′-deoxy-1-β-D-arabinofuranosyl-5-iodouracil.1 Bioluminescence 
imaging (BLI) of luciferase reporter gene expression has also been used to monitor 
lymphocyte trafficking in a mouse model.2,3 Recently Dobrenkov et al.4 have shown the 
feasibility of PET and BLI in a prostate cancer model using peripheral blood chimeric 
antigen receptor (CAR)+ cells and Jensen and co-workers have evaluated the biodistribution 
of CAR+ T cells by magnetic resonance imaging.5
Previously, we have demonstrated that human T cells derived from peripheral blood and 
umbilical cord blood (UCB) mononuclear cells can be rendered specific for CD19 by the 
introduction of a CAR.3,6 To track the persistence of infused genetically modified T cells, a 
HHS Public Access
Author manuscript
Leukemia. Author manuscript; available in PMC 2016 November 14.
Published in final edited form as:













multi-function reporter gene (designated ffLucHyTK) was developed which fuses firefly 
luciferase (ffLuc), hygromycin phosphotransferase (Hy) and HSV-TK (Figure 1).2,3 The 
four-function reporter transgene can achieve (i) in vitro selection of genetically modified T 
cells in cytocidal concentrations of hygromycin B, (ii) in vivo ganciclovir-dependent 
conditional ablation7 and in vivo imaging with (iii) BLI with (iv) PET. A DNA plasmid 
expressing the fusion gene was expressed in T cells to render them resistant to cytocidal 
concentrations of hygromycin B and thus co-express the ffLuc and TK imaging genes.
This was achieved using UCB-derived T cells that underwent electro-transfer with the 
plasmid ffLucHyTK-pMG (Figure 1a). We demonstrated that the genetically modified and 
propagated TK+ T cells could be visualized by selective incorporation of radiolabeled 2′-
fluoro-2′deoxy-1-β-D-arabionofuranosyl-5-ethyl-uracil (FEAU) in a xenogenic mouse 
model. Radiolabeled FEAU is a specific substrate for HSV1-TK enzyme, which accumulates 
in HSV1-TK-transfected cells through phosphorylation by the HSV1-TK enzyme, and that 
the magnitude and spatial distribution of accumulation of FEAU-derived radioactivity in the 
body reflects the location and density of TK+ cells. Initially, in vitro uptake studies were 
conducted to evaluate the accumulation and retention of [3H]FEAU. The genetically 
modified T cells exhibited selective accumulation of FEAU as compared with untransfected 
T cells (1185 and 6031 disintegrations per minute (DPM)/mg protein respectively) (Figure 
1d). The proliferation rate of transfected and untransfected cells was equivalent as 
demonstrated by [14C]-labeled thymidine uptake. The HSV-TK-derived enzymatic activity 
detected by in vitro accumulation of FEAU was high and adequate for in vivo imaging with 
microPET.
To visualize genetically modified UCB-derived T cells by BLI and µPET, nude mice were 
injected subcutaneously (right hind leg) or intravenously through tail vein and imaged using 
an ultrasensitive CCD camera followed by a µPET scan. Bioluminescent images after 
intraperitoneal injection of D-Luciferin revealed that genetically modified T cells express 
high bioluminescence (2.22 × 105 p/sec/cm2/sr) in comparison to the control (left uninjected 
leg) (0.29 × 105 p/sec/cm2/sr). These mice were then imaged by µPET using intravenous 
infusion of [18F]FEAU and static images were obtained. The signal from the images was 
used to determine % injected dose (ID)/g of FEAU which is a measure of the amount of 
tracer accumulated in a given tissue site normalized to the injected amount and to the mass 
of tissue examined. The %ID/g value for genetically modified T cells (7.9%) was higher 
than the control (muscle, 1.61%) (Figure 2a). After intravenous infusion of genetically 
modified UCB-derived T cells, the cells could be visualized in the lung both by BLI and 
µPET. Ratio of bioluminescent signals from lungs and control tissue (abdomen) was 36. PET 
images reveal the accumulation of radiotracer in the lungs along with the urinary bladder 
(Figure 2b).
These data indicate that the genetically modified UCB-derived T cells expressing the 
ffLucHyTK fusion transgene can uptake PET-tracer in vitro and can be visualized 
spatiotemporally in vivo by both BLI and µPET. As the ffLucHyTK is similar to the HyTK 
transgene used in clinical trials9 these data can be used to provide the proof-of-principle for 
instituting PET imaging after infusion of donor-derived T cells following UCB 
transplantation.
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This is the first report demonstrating that HyTK fusion gene can be used not only for 
selection and suicide,3 but also for PET using T cells from UCB. This has translational 
importance as the TK and HyTK transgenes are currently used in clinical trials,7,9 where co-
expression of the TK suicide gene may be necessary to ensure safety of initial protocols 
infusing genetically modified T cells. As investigators proceed with infusing genetically 
modified T cells, including from umbilical cord blood, the incorporation of PET imaging is 
expected to be a useful biologic end point.
Acknowledgments
Support from Cancer Center Core Grant (CA16672); RO1 (CA124782, CA120956); R21 (CA129390, CA116127); 
DOD (PR064229); The Alliance for Cancer Gene Therapy; The Alex Lemonade Stand Foundation; The Carl C 
Anderson, Sr and Marie Jo Anderson Charitable Foundation; The Gillson Longenbaugh Foundation; The JP 
McCarthy Fund Developmental Grant Program The Leukemia and Lymphoma Society; The Lymphoma Research 
Foundation; The Miller Foundation, The National Foundation for Cancer Research; The National Marrow Donor 
Program; The Pediatric Cancer Research Foundation.
References
1. Tjuvajev JG, Avril N, Oku T, Sasajima T, Miyagawa T, Joshi R, et al. Imaging herpes virus 
thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res. 1998; 
58:4333–4341. [PubMed: 9766661] 
2. Singh H, Serrano LM, Pfeiffer T, Olivares S, McNamara G, Smith DD, et al. Combining adoptive 
cellular and immunocytokine therapies to improve treatment of B-lineage malignancy. Cancer Res. 
2007; 67:2872–2880. [PubMed: 17363611] 
3. Serrano LM, Pfeiffer T, Olivares S, Numbenjapon T, Bennitt J, Kim D, et al. Differentiation of naive 
cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive 
immunotherapy. Blood. 2006; 107:2643–2652. [PubMed: 16352804] 
4. Dobrenkov K, Olszewska M, Likar Y, Shenker L, Gunset G, Cai S, et al. Monitoring the efficacy of 
adoptively transferred prostate cancer-targeted human T lymphocytes with PET and 
bioluminescence imaging. J Nucl Med. 2008; 49:1162–1170. [PubMed: 18552144] 
5. Lazovic J, Jensen MC, Ferkassian E, Aguilar B, Raubitschek A, Jacobs RE. Imaging immune 
response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme. 
Clin Cancer Res. 2008; 14:3832–3839. [PubMed: 18559603] 
6. Cooper LJ, Topp MS, Serrano LM, Gonzalez S, Chang WC, Naranjo A, et al. T-cell clones can be 
rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage 
leukemia effect. Blood. 2003; 101:1637–1644. [PubMed: 12393484] 
7. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, et al. HSV-TK gene transfer 
into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997; 276:1719–
1724. [PubMed: 9180086] 
8. Soghomonyan S, Hajitou A, Rangel R, Trepel M, Pasqualini R, Arap W, et al. Molecular PET 
imaging of HSV1-tk reporter gene expression using [18F]FEAU. Nat Protoc. 2007; 2:416–423. 
[PubMed: 17406603] 
9. Jensen MC, Popplewell L, DiGiusto DL, Kalos M, Cooper LJN, Raubitschek A, et al. A first-in-
human clinical trial of adoptive therapy using CD19-specific chimeric antigen receptor re-directed T 
cells for recurrent/refractory follicular lymphoma. Mol Ther. 2007; 15:S142.
Singh et al. Page 3














(a) Schematic of the fusion transgene ffLucHyTK expressed from the DNA plasmid 
ffLucHyTK-pMG.3 (b) Luciferase activity of genetically modified T cells, incubated with 
D-Luciferin (1.43 mg/ml in 200 µl) in a 96-well Opti-plate and the luminescence measured 
(CPM) using TopCount (Perkin-Elmer). (c) 2′-Deoxy-2′-[18F]fluoro-5-ethyl-1-β-D-
arabinofuranosyluracil ([18F]-FEAU) was synthesized as described earlier.8 Briefly, 1,3,5-
tri-O-benxoyl-2-trifluoromethasulfonyl-ribose was radiolabeled with 18F-fluoride using 
Bu4N18F to the corresponding 2-18F-fluoro-arabinose. The 2-18F-fluoro-arabinose was then 
converted to its 1-bromo-derivative, which was condensed with protected 5-ethyluracil. 
Hydrolysis of the protecting groups in the sugar moiety with NaOMe produced the desired 
radiolabeled nucleoside, which was purified by HPLC. Solvent was evaporated, and then the 
product was re-constituted in saline and filtered through a 0.22 µ Millipore filter. The 
radiochemical yield was 20% (decay corrected, d.c.) from the end of bombardment. 
Radiochemical purity was > 99% and specific activity was > 74 GBq/µmol. (d) In vitro 
radiotracer uptake study, genetically modified or unmanipulated T cells (107) were 
centrifuged (1000 g, 5 min) and the pellet was resuspended in 6ml of RPMI media 
containing 10% fetal bovine serum and the radiotracers [14C]-thymidine (0.01 µCi/ml) 
(Moravek, Brea, CA, USA) and [3H]-FEAU (0.1 µCi/ml) (Moravek). The cell suspension 
was subsequently divided into three 10mm2 dishes (2 ml per dish) and incubated for 120 
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min. Each suspension was then transferred into a 15ml tube, and centrifuged at 1000 g for 2 
min. A 100 µl aliquot of supernatant was transferred to a pre-weighed scintillation tube, and 
the rest was removed by aspiration before snap-freezing the cell pellet on dry ice. The frozen 
pellets were transferred to pre-weighed scintillation vials, weighed and thoroughly 
resuspended in 0.5 ml of Soluene-350 (Perkin-Elmer, Boston, MA, USA) before adding 4ml 
of Insta-Fluor Plus scintillation fluid (Perkin-Elmer). Radioactive β emissions of the media 
and the cell pellets were measured within precalibrated energy ranges using a Packard Tri-
Carb 3100TR scintillation counter to quantitate [3H]-FEAU and [14C]-thymidine uptakes. 
Activity accumulation ratios of cell pellet to media ((DPM/g cells)/(DPM/g media)) were 
then determined and plotted.
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Bioluminescent and µPET imaging. To non-invasively track the UCB-derived T cells in vivo, 
a DNA plasmid expressing the reporter gene ffLucHyTK was introduced by non-viral gene 
transfer. Nude mice were injected with ffLucHyTK+ UCB-derived T cells (a) 
intramuscularly (106) and (b) intravenously (107). Bioluminescent imaging (Xenogen-IVIS 
model 200 Imaging System) of the genetically modified T cells was performed 5 min 
following an intraperitoneal injection of D-luciferin (Xenogen Corp; 2 mg/Kg in PBS). 
MicroPET imaging (Concorde Microsystem Roden R4 microPET) was performed after 
intravenous injection of radiotracer [18F]-FEAU (3.7MBq in 100 µl of saline) and following 
a 2-h incubation, static PET images were acquired. PET images were then reconstructed 
using ordered subset expectation maximization algorithms with subsets 16 and iteration 4. 
Regional radioactivity concentrations of organs for [18F]-FEAU were estimated by regions 
of interest (ROI) drawn around the organ on the reconstructed image. The radiotracer uptake 
levels in the blood (aorta), and muscle were determined and expressed as percent injected 
dose per gram (%ID/g)±s.d.
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